Latent or low-level persistent reservoirs of HIV-1 may be the chief hurdle to eradication of infection. In particular, it is thought that latently infected T cells can harbor integrated virus, which cannot be eliminated by current therapeutics. Therefore if therapy is discontinued for any reason, this reservoir rekindles infection. Additional potential reservoirs, such as macrophages or microglia in the brain could serve as long-lived sources of low-level virus production. It is thus imperative to identify and model means to eliminate these reservoirs. This proposal aims to use an in Vivo model, the recently described "BLT mouse" to assess methods to attack latent reservoirs by an "induction/eradication" strategy. We will perform studies to test the concept that activation of latently infected cells, followed by introduction of specific agents designed to kill cells induced to newly express virus, will provide a means of purging these resevoirs in vivo. We will accomplish our goals through the following three Specific Aims: 1) Define the reservoirs of latent virus established by different HIV strains in BLT mice;2) Determine the effects of anfi-HIV immunotoxin on latent reservoirs in vivo;3) Determine the capacity of genefically engineered cytotoxic T cells to impact viral reservoirs in vivo. The studies proposed herein will develop a valuable in vivo system to examine HIV latency, and may provide proof-of-principle that targeted immunoreagents may facillitate clearence of HIV reservoirs following inducfion of expression of the latent virus.
Latent or persistent HIV reservoirs are impervious to standard antiretroviral therapy, thus they stand as the chief obstacle to clearence of virus from the body. This project proposes to utilize a novel in vivo humanized mouse model to test strategies based on induction and subsequent targeted elimination of viral reservoirs. If successful, a new type of treatment strategy may be developed based on results obtained.
|Davis, Zachary B; Cogswell, Andrew; Scott, Hamish et al. (2016) A Conserved HIV-1-Derived Peptide Presented by HLA-E Renders Infected T-cells Highly Susceptible to Attack by NKG2A/CD94-Bearing Natural Killer Cells. PLoS Pathog 12:e1005421|
|Imaz, Arkaitz; Martinez-Picado, Javier; NiubÃ³, Jordi et al. (2016) HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen. J Infect Dis 214:1512-1519|
|Honeycutt, Jenna B; Wahl, Angela; Baker, Caroline et al. (2016) Macrophages sustain HIV replication in vivo independently of T cells. J Clin Invest 126:1353-66|
|Tokarev, Andrey; Stoneham, Charlotte; Lewinski, Mary K et al. (2016) Pharmacologic Inhibition of Nedd8 Activation Enzyme Exposes CD4-Induced Epitopes within Env on Cells Expressing HIV-1. J Virol 90:2486-502|
|Victor Garcia, J (2016) Humanized mice for HIV and AIDS research. Curr Opin Virol 19:56-64|
|Smith, Davey M; Nakazawa, Masato; Freeman, Michael L et al. (2016) Asymptomatic CMV Replication During Early Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower CD4/CD8 Ratio During HIV Treatment. Clin Infect Dis 63:1517-1524|
|Gianella, Sara; Anderson, Christy M; Var, Susanna R et al. (2016) Replication of Human Herpesviruses Is Associated with Higher HIV DNA Levels during Antiretroviral Therapy Started at Early Phases of HIV Infection. J Virol 90:3944-52|
|Garcia, J Victor (2016) In vivo platforms for analysis of HIV persistence and eradication. J Clin Invest 126:424-31|
|Lee, Sook-Kyung; Zhou, Shuntai; Baldoni, Pedro L et al. (2016) Quantification of the Latent HIV-1 Reservoir Using Ultra Deep Sequencing and Primer ID In A Viral Outgrowth Assay. J Acquir Immune Defic Syndr :|
|Wagner, Gabriel A; Chaillon, Antoine; Liu, Siqi et al. (2016) HIV-associated neurocognitive disorder is associated with HIV-1 dual infection. AIDS 30:2591-2597|
Showing the most recent 10 out of 187 publications